Richard Jed Wyatt

Richard Jed Wyatt's AcademicInfluence.com Rankings

Richard Jed Wyatt

Psychology

#1240

World Rank

#1527

Historical Rank

Clinical Psychology

#61

World Rank

#61

Historical Rank

psychology Degrees

Download Badge

Psychology

Why Is Richard Jed Wyatt Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard Jed Wyatt's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Measurement of premorbid adjustment in chronic schizophrenia. (1982) (1126)
An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks (1982) (1099)
Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. (1979) (949)
The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. (1997) (941)
Neuroleptics and the natural course of schizophrenia. (1991) (768)
Lateral cerebral ventricular enlargement in chronic schizophrenia. (1979) (544)
Schizophrenia, just the facts What do we know, how well do we know it? (1988) (500)
Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour (1981) (414)
Preventing recurrent homelessness among mentally ill men: a "critical time" intervention after discharge from a shelter. (1997) (357)
Platelet and plasma amine oxidase activity in 680 normals: Sex and age differences and stability over time (1976) (354)
Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: Long‐term behavioral, biochemical, and histochemical studies (1980) (345)
Reduced Monoamine Oxidase Activity in Blood Platelets from Schizophrenic Patients (1972) (338)
Computed tomography in schizophreniform disorder and other acute psychiatric disorders. (1982) (309)
Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment. (1980) (305)
An economic evaluation of manic-depressive illness-1991 (1995) (288)
Reduced Monoamine Oxidase Activity in Platelets: A Possible Genetic Marker for Vulnerability to Schizophrenia (1973) (285)
Poor premorbid adjustment and CT scan abnormalities in chronic schizophrenia. (1980) (267)
The flower pot technique of rapid eye movement (REM) sleep deprivation. (1974) (264)
Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. (2000) (262)
Neurotransmitter receptors in frontal cortex of schizophrenics. (1979) (256)
Resting plasma catecholamine concentrations in patients with depression and anxiety. (1971) (243)
Brain electrical activity mapping (BEAM) in schizophrenic patients. (1983) (240)
Structural abnormalities in the cerebral cortex of chronic schizophrenic patients. (1979) (240)
REM sleep induction by physostigmine infusion during sleep. (1976) (226)
Understanding and Treating Tardive Dyskinesia (1982) (221)
Phenylethylamine in paranoid chronic schizophrenia. (1979) (218)
Calcitonin: inhibitory effect on eating in rats. (1979) (217)
Age-related changes in sleep in depressed and normal subjects (1981) (213)
Neuropathological studies of schizophrenia: a selective review. (1983) (201)
Cerebellar pathology in schizophrenia: a controlled postmortem study. (1980) (195)
Paternal age and risk of schizophrenia in adult offspring. (2002) (186)
The Na,K-ATPase hypothesis for bipolar illness (1995) (185)
Biogenic amine-related enzymes and personality variations in normals (1977) (182)
Tardive dyskinesia--reversible and persistent. (1979) (181)
Intravenous naloxone administration in schizophrenia and affective illness. (1977) (169)
Platelet monoamine oxidase activity in schizophrenia: a review of the data. (1979) (156)
Familial aspects of CT scan abnormalities in chronic schizophrenic patients (1981) (156)
Schizophrenia: evidence of a subgroup with reversed cerebral asymmetry. (1979) (152)
An economic evaluation of schizophrenia-1991 (1995) (147)
When symptoms persist: choosing among alternative somatic treatments for schizophrenia. (1991) (145)
Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. (1971) (144)
Effects of L-tryptophan (a natural sedative) on human sleep. (1970) (143)
Changing epidemiology of tardive dyskinesia: an overview. (1981) (142)
Therapeutic strategies against tardive dyskinesia. Two decades of experience. (1982) (141)
Metabolism of (‐) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit (1982) (140)
Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia (1994) (139)
A negative symptom rating scale (1985) (137)
Treatment of schizophrenia 1999 (1999) (136)
Human Sleep and Its Disorders (1977) (135)
Monamine oxidase in schizophrenia and other behavioral disorders. (1974) (132)
Human platelet monoamine oxidase changes during the menstrual cycle. (1974) (132)
BRAIN CONCENTRATIONS OF BIOGENIC AMINE METABOLITES IN ACUTELY TREATED AND ETHANOL‐DEPENDENT RATS (1976) (132)
Treatment of tardive dyskinesia with vitamin E. (1992) (131)
Speaking, thinking, and blinking (1981) (129)
Region-selective stress-induced increase of glutamate uptake and release in rat forebrain (1990) (128)
Normalization of spiroperidol binding in the denervated rat striatum by homologous grafts of substantia nigra. (1983) (124)
CEREBELLAR ATROPHY IN CHRONIC SCHIZOPHRENIA (1979) (124)
Early intervention for schizophrenia: Can the course of the illness be altered? (1995) (123)
Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as cause of death. (1986) (123)
Risk factors for spontaneous dyskinesia in schizophrenia. (1994) (120)
Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms (1995) (119)
Telemetered EEG-EOG during psychotic behaviors of schizophrenia. (1979) (119)
Cognitive Impairment Associated with Morphological Brain Abnormalities on Computed Tomography in Chronic Schizophrenic Patients (1980) (119)
Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials (2000) (113)
Increased whole blood serotonin concentrations in chronic schizophrenic patients. (1981) (112)
The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. (1976) (112)
Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data (1997) (112)
Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. (1999) (111)
Adrènal medulla grafts survice and exhibit catecholamine-specific fluorescence in the primate brain (1984) (110)
Treatment of tardive dyskinesia. (1997) (107)
Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine. (1970) (106)
Promoting functional plasticity in the damaged nervous system. (1985) (105)
Sleep disturbance in acute schizophrenic patients. (1970) (105)
Dopamine beta-hydroxylase activity in brains of chronic schizophrenic patients. (1975) (104)
Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. (1972) (103)
The design of the prenatal determinants of schizophrenia study. (2000) (103)
Methoscopolamine inhibition of sleep-related growth hormone secretion. Evidence for a cholinergic secretory mechanism. (1978) (103)
Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. (1996) (102)
Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. (1988) (102)
MASS FRAGMENTOGRAPHY OF PHENYLETHYLAMINE, m‐ AND p‐TYRAMINE AND RELATED AMINES IN PLASMA, CEREBROSPINAL FLUID, URINE, AND BRAIN (1979) (100)
6-18F-DOPA PET study in patients with schizophrenia (2000) (100)
Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. (1983) (100)
The neuropharmacology of sleep and wakefulness. (1978) (100)
Mass‐fragmentography of nanogram quantities of biogenic amine metabolites in human cerebrospinal fluid and whole rat brain (1975) (99)
Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. (1971) (98)
Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. (1994) (97)
Rationale for the study of early intervention (2001) (96)
Are paranoid schizophrenics biologically different from other schizophrenics? (1978) (96)
Cost-effectiveness of critical time intervention to reduce homelessness among persons with mental illness. (2003) (95)
Maternal prepregnant body mass and risk of schizophrenia in adult offspring. (2000) (95)
Did schizophrenia exist before the eighteenth century? (1985) (94)
The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep (1977) (93)
Monoamine oxidase in schizophrenia: an overview. (1980) (92)
Catecholamine content of intracerebral adrenal medulla grafts (1983) (91)
A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients (1981) (90)
Schizophrenia and cerebral asymmetry detected by computed tomography. (1982) (89)
An analysis of lymphocyte subpopulations in schizophrenic patients. (1982) (89)
Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. (1987) (87)
A dimethyltryptamine-forming enzyme in human blood. (1973) (87)
Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. (1981) (87)
In search of treatment for tardive dyskinesia: review of the literature. (1979) (86)
Calcitonin reduces feeding in man, monkey and rat (1980) (86)
Effects of melatonin and propranolol on sleep of the rat (1980) (85)
Intact retention in acute alcohol amnesia. (1984) (85)
Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic‐induced dyskinesias (1994) (84)
Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. (1987) (83)
Peripheral nerve reconnection: Mechanical, thermal, and ionic conditions that promote the return of function (1983) (83)
ALPHA-TOCOPHEROL IN TARDIVE DYSKINESIA (1987) (82)
Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients. (1981) (81)
A critical time intervention with mentally ill homeless men: impact on psychiatric symptoms. (2000) (81)
13. Early intervention with neuroleptics may decrease the l long-term morbidity of schizophrenia (1991) (80)
Cocaine-induced reduction of brain neuropeptide Y synthesis dependent on medial prefrontal cortex. (1991) (78)
Reduced haloperidol in the post-mortem brains of haloperidol-treated patients (1984) (78)
6‐[18F]fluoro‐L‐DOPA PET studies of the turnover of dopamine in MPTP‐induced parkinsonism in monkeys (1998) (78)
Rat sciatic functional index data management system with digitized input. (1984) (77)
MASS FRAGMENTOGRAPHIC DETERMINATION OF SOME ACIDIC AND ALCOHOLIC METABOLITES OF BIOGENIC AMINES IN THE RAT BRAIN (1975) (77)
Platelet monoamine oxidase activity in acute schizophrenia. (1975) (75)
Not all that moves is tardive dyskinesia. (1991) (74)
Dopamine-sensitive adenylyl cyclase in human caudate nucleus. A study in control subjects and schizophrenic patients. (1975) (74)
Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication (1994) (74)
Seizures with Antidepressants: An In Vitro Technique to Assess Relative Risk (1984) (73)
Low platelet monoamine oxidase activity and schizophrenia. (1976) (73)
Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. (1983) (73)
All-night sleep studies of acute schizophrenics. (1969) (72)
Effect of L-Dopa on the Sleep of Man (1970) (72)
Serum cytokine concentrations in patients with schizophrenia (1996) (72)
Chronic cocaine and rat brain catecholamines: long-term reduction in hypothalamic and frontal cortex dopamine metabolism. (1990) (72)
The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline (1978) (72)
Aluminum and Alzheimer's Disease (1983) (69)
Multiple forms of brain monoamine oxidase in schizophrenic and normal individuals. (1974) (69)
Effects of 5-hydroxytryptophan on the sleep of normal human subjects. (1971) (69)
Plasma prolactin concentrations and psychopathology in chronic schizophrenia. (1982) (68)
Follow-up of chronically homeless mentally ill men. (1993) (67)
REM inhibitory effect of L-DOPA infusion during human sleep. (1973) (66)
Phenomenologic Comparison of the Idiopathic Psychosis of Schizophrenia and Drug‐Induced Cocaine and Phencyclidine Psychoses: A Retrospective Study (1994) (66)
Effects of para-chlorophenylalanine on sleep in man. (1969) (64)
Gaze discrimination in patients with schizophrenia: preliminary report. (1994) (64)
Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine. (1985) (64)
Piperidine enhances sleep-related and insulin-induced growth hormone secretion: further evidence for a cholinergic secretory mechanism. (1981) (64)
The Hippocampal Slice: A System for Studying the Pharmacology of Seizures and for Screening Anticonvulsant Drugs (1977) (63)
Elevated blood serotonin concentrations in unmediated chronic schizophrenic patients: a preliminary study. (1975) (63)
The effects of early and sustained intervention on the long-term morbidity of schizophrenia. (1998) (63)
Retrograde enhancement of human memory with alcohol (2004) (62)
Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice (1984) (62)
Part I. Biochemical Studies (1971) (61)
Tryptoline formation by a preparation from brain with 5-methyltetrahydrofolic acid and tryptamine. (1975) (60)
Transplantation of Catecholamine-Containing Tissues to Restore the Functional Capacity of the Damaged Nigrostriatal System (1984) (59)
Muscarinic cholinergic binding sites on intact human lymphocytes. (1981) (59)
Lithium: a brake in the rising cost of mental illness. (1980) (58)
Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. (1992) (57)
Neuroleptic-induced seizures. An in vitro technique for assessing relative risk. (1982) (57)
Tryptolines. Formation from tryptamines and 5-MTHF by human platelets. (1974) (56)
Lithium carbonate and sleep in affective illness. (1970) (56)
Wheat gluten challenge in schizophrenic patients. (1981) (56)
The dynamics of dopamine metabolism in various regions of rat brain. (1977) (56)
Research in schizophrenia and the discontinuation of antipsychotic medications. (1997) (55)
Burned-out schizophrenia: evidence for age effects on schizophrenic symptomatology. (1978) (55)
Platelet monamine oxidase in chronic schizophrenia. Some enzyme characteristics relevant to reduced activity. (1976) (55)
Monozygotic twins discordant for schizophrenia are discordant for N-CAM and L1 in CSF (1997) (55)
CEREBRAL VENTRICULAR SIZE: A BIOLOGICAL MARKER FOR SUB-TYPING CHRONIC SCHIZOPHRENIA (1982) (55)
Photic regulation of the melatonin rhythm: monkey and man are not the same (1980) (54)
Pharmacological treatments of tardive dyskinesia in the 1980s. (1988) (53)
Cerebral asymmetry and cerebellar atrophy in schizophrenia: a controlled postmortem study. (1981) (53)
GABA concentrations in forebrain areas of suicide victims (1988) (53)
Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain (1994) (53)
Chronic cocaine administration increases tyrosine hydroxylase activity in the ventral tegmental area through glutaminergic- and dopaminergic D2-receptor mechanisms (1996) (53)
A comparison of equivalent clinical potencies of neuroleptics as used to treat schizophrenia and affective disorders. (1977) (53)
Interleukin-1α and interleukin-2 in cerebrospinal fluid of schizophrenic subjects (1993) (51)
Persistently decreased brain dopamine levels and cocaine. (1988) (51)
The Dopamine Hypothesis: Variations on a Theme (1985) (51)
Polydipsia and chronic hyponatremia in schizophrenic inpatients. (1985) (51)
Childhood experiences and current adjustment of offspring of indigent patients with schizophrenia. (1998) (51)
Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. (1985) (51)
Eye-blink rates and platelet monoamine oxidase activity in chronic schizophrenic patients. (1980) (50)
Drug effect on blink rates in rhesus monkeys: preliminary studies. (1981) (50)
Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. (1982) (50)
Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients (1987) (50)
Elevated concentration of N-CAM VASE isoforms in schizophrenia. (2000) (50)
Treatment of insomnia. (1973) (50)
Brain Catecholamines and Human Sleep (1971) (49)
Platelet monoamine oxidase activity: demographic characteristics contribute to enzyme activity variability. (1985) (49)
The alcohol facilitation effect on memory: A dose-response study (2004) (49)
Chlorpromazine and sleep in psychiatric patients. (1971) (49)
Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity? (1981) (48)
Quantitative Determination of Immunoglobulins in CSF and Plasma of Chronic Schizophrenic Patients (1981) (48)
The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. (1991) (48)
Neuroleptics decrease blinking in schizophrenic subjects. (1981) (48)
The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. (1980) (48)
Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. (1982) (48)
Low platelet monoamine oxidase activity and chronic marijuana use. (1978) (47)
SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. (1999) (47)
Platelet monoamine oxidase in chronic schizophrenic patients. (1978) (47)
Sleep during chronic ethanol administration and withdrawal in rats. (1978) (47)
Ventricular brain enlargement and outcome of acute schizophreniform disorder (1983) (47)
Murder and assault arrests of White House cases: clinical and demographic correlates of violence subsequent to civil commitment. (1989) (46)
Fewer dopamine transporter receptors in the prefrontal cortex of cocaine users. (1994) (46)
Fluctuating high urinary phenylethylamine excretion rates in some bipolar affective disorder patients (1982) (45)
Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. (1985) (45)
In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long‐term MPTP‐induced parkinsonism (2000) (44)
Estimation of the contribution of peripheral and central noradrenergic neurones to urinary 3-methoxy-4-hydroxyphenylglycol in the rat. (1974) (44)
Biochemical evidence for uncrossed and crossed locus coeruleus projections to the spinal cord (1980) (44)
An evaluation of a mental health program for homeless men. (1990) (44)
Absence of 6‐Hydroxydopamine in the Rat Brain After Treatment with Stimulants and Other Dopaminergic Agents: A Mass Fragmentographic Study (1993) (44)
Effects of Single and Repeated Footshock on Dopamine Release and Metabolism in the Brains of Fischer Rats (1997) (44)
Peripheral nerve reconnection: Improvement of long-term functional effects under simulated clinical conditions in the rat (1983) (44)
Phenylethylamine excretion in attention deficit disorder. (1984) (43)
Filicide during psychotropic-induced somnambulism: a case report. (1978) (43)
The Schizophrenia Syndrome: Examples of Biological Tools for Subclassification (1981) (42)
Evaluation of CT scans in tardive dyskinesia. (1980) (42)
On elaboration and alcohol (1983) (42)
Abnormal immune regulation in schizophrenic patients. (1982) (42)
Low platelet monoamine oxidase and vulnerability to schizophrenia. (1975) (41)
The activity of dopamine-beta-hydroxylase and methionine-activating enzyme in blood of schizophrenic patients. (1973) (41)
Dose-response effects of beta-phenylethylamine on stereotyped behavior in pargyline-pretreated rats. (1976) (41)
Anomalous behavioral response to imidazoleacetic acid, a GABA agonist, in animals treated chronically with haloperidol. (1980) (40)
Immunocytochemical localization of neuropeptide Y-like immunoreactivity in adrenergic and non-adrenergic neurons of the rat gastrointestinal tract (1987) (40)
Sources of error in the determination of platelet monoamine oxidase: a review of methods. (1980) (40)
Effects of chronic cocaine administration on [3H]dopamine uptake in the nucleus accumbens, striatum and frontal cortex of rats. (1994) (40)
Use of calcitonin in psychotic agitation or mania. (1979) (40)
Reduced metabolism and turnover rates of rat brain dopamine, norepinephrine and serotonin by chronic desipramine and zimelidine treatments. (1984) (39)
Partial REM sleep deprivation, schizophrenia and field articulation. (1974) (39)
Effect of prolonged chlorpromazine administration on the sleep of chronic schizophrenics. (1974) (39)
Risks of withdrawing antipsychotic medications. (1995) (39)
Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia (2005) (39)
Failure of N,N-dimethyltryptamine to evoke tolerance in cats. (1973) (39)
biochemical and sleep studies of schizophrenia: a review of the literature—1960-1970 part I. biochemical studies (1970) (39)
Noradrenergic and neuroradiological abnormalities in tardive dyskinesia (1986) (39)
HLA Antigens in Schizophrenia: Differences between Patients with and without Evidence of Brain Atrophy (1980) (38)
Phenylacetic acid excretion in schizophrenia and depression: the origins of PAA in man. (1984) (38)
Brain-derived and glial cell line-derived neurotrophic factors protect a catecholaminergic cell line from dopamine-induced cell death (1999) (38)
Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. (1988) (37)
Haloperidol-Induced Changes in Blink Rates Correlate with Changes in BPRS Score (1982) (37)
Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements (1994) (37)
First-episode schizophrenia (1998) (36)
On the orthomolecular environment of the mind: orthomolecular theory. (2015) (36)
Decreased DOPAC in the anterior cingulate cortex of individuals with schizophrenia (1995) (36)
MONOAMINE OXIDASE IN SCHIZOPHRENIA AND OTHER BEHAVIORAL DISORDERS (1975) (36)
Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? (1999) (36)
Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients (1992) (36)
Trans-synaptic modulation of dopamine metabolism in the rat superior cervical ganglion. (1977) (35)
Incidence and cumulative risk of treated schizophrenia in the prenatal determinants of schizophrenia study. (2000) (35)
Muscarinic binding in suicides (1984) (35)
Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics (1995) (35)
Calcium: bivalent cation in the bivalent psychoses. (1979) (34)
Substance P afferents from the habenula innervate the dorsal raphe nucleus (2004) (34)
Reduction of REM sleep by a tryptophan-free amino acid diet. (1979) (33)
Effects of Catechol-O-methyltransferase Inhibition on the Rates of Uptake and Reversibility of 6-Fluoro-l-Dopa Trapping in MPTP-induced Parkinsonism in Monkeys (1997) (33)
An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. (1996) (33)
Habenular modulation of raphe indoleamine metabolism. (1980) (33)
9 -Transtetrahydrocannabinol and natural marihuana. A controlled comparison. (1973) (33)
Selective effects of phenylethylamine on central catecholamines: a comparative study with amphetamine. (1982) (32)
High serum neuroleptic levels in tardive dyskinesia? (1979) (32)
Calcium: pacesetting the periodic psychoses. (1979) (32)
CATECHOLAMINES AND METABOLITES IN THE BRAINS OF PSYCHOTICS AND NORMALS: POST-MORTEM STUDIES (1979) (32)
Phenylacetic acid excretion in man. (1979) (31)
Height, weight and body mass index (BMI) in psychiatrically ill US Armed Forces personnel (2003) (31)
A biochemical study of tardive dyskinesia in young male patients (1981) (31)
Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients (1988) (31)
Effects of acute and chronic clozapine and haloperidol administration on 3-methoxytyramine accumulation in rat prefrontal cortex, nucleus accumbens and striatum. (1991) (31)
Eye-blinking and cerebral ventricular size in chronic schizophrenic patients. (1984) (31)
Kindling induces long-lasting alterations in response of hippocampal neurons to elevated potassium levels in vitro. (1980) (31)
Evidence for a frontocortical-septal glutamatergic pathway and compensatory changes in septal glutamate uptake after cortical and fornix lesions in the rat (1991) (31)
Clinical effects of tryptophan in chronic schizophrenic patients. (1976) (30)
Cross-cultural study of a biochemical abnormality in paranoid schizophrenia (1981) (30)
Famotidine Adjunctive Pharmacotherapy for Schizophrenia: Preliminary Data (1993) (30)
Serotonin concentrations in brain and blood of scrapie-infected and normal hamsters and mice (1981) (29)
Characteristics of [3H]GBR 12935 Binding in the Human and Rat Frontal Cortex (1991) (29)
Marijuana and synthetic 9-trans-tetrahydrocannabinol: some effects on the auditory evoked response and background EEG in humans. (1973) (29)
Association of abnormal involuntary movements and negative symptoms. (1984) (29)
Marihuana and social behavior; a controlled study. (1974) (29)
Increased dopamine and norepinephrine concentrations in primate CSF following amphetamine and phenylethylamine administration (1980) (29)
The long-term effects of placebo in patients with chronic schizophrenia (1999) (28)
Arginine vasotocin and sleep in the rat (1980) (28)
Anomalous lateralization associated with a milder form of schizophrenia. (1979) (28)
Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia. (1983) (28)
Biochemistry and schizophrenia (part IV) the neuroleptics--their mechanism of action: a review of the biochemical literature. (1976) (28)
Neurodevelopmental abnormalities and schizophrenia. A family affair. (1996) (28)
Liquid-chromatographic quantification of plasma phenylalanine, tyrosine, and tryptophan. (1981) (28)
State-dependent (dissociative) effects of marihuana on human memory. (1974) (28)
Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study. (1981) (27)
POSTMORTEM NEUROCHEMICAL STUDIES IN CHRONIC SCHIZOPHRENIA (1982) (27)
A correlation between platelet monoamine oxidase activity and plasma prolactin concentrations in man. (1979) (27)
Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine. (1977) (27)
Serendipity in biological psychiatry--a myth? (1979) (27)
Regional differences in catecholamine formation and metabolism in the rat spinal cord (1981) (27)
Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration. (2009) (27)
Impairment of instrumental learning in rats by glutamic acid diethyl ester (1981) (26)
Use of narcotic antagonists to study the role of endorphins in normal and psychiatric patients (1979) (26)
Effects of haloperidol, lithium, and valproate on phosphoinositide turnover in rat brain (1993) (26)
REDUCTION OF SERUM-PROLACTIN AFTER SUBCUTANEOUS SALMON CALCITONIN (1977) (26)
Paraphrenia: Paranoid States of Late Life. I. European Research (1980) (25)
Effect of Chronic Nicotine Treatment and Withdrawal on Rat Striatal D1 and D2 Dopamine Receptors (1992) (25)
Polyamines modulate the binding of GABAA-benzodiazepine receptor ligands in membranes from the rat forebrain (1992) (25)
Primary affective disorder: thought disorder in depression. (1980) (25)
Neuroleptic-associated tardive syndromes. (1986) (25)
Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects (2004) (25)
HLA antigens in schizophrenia (1990) (25)
Effect of dopamine agonists and antagonists on the electrical activity of substantia nigra neurons transplanted into the lateral ventricle of the rat (2004) (25)
HLA-A2 Antigen in Schizophrenic Patients with Reversed Cerebral Asymmetry (1981) (25)
The effect of orally administered cocaine on sleep of depressed patients (1974) (24)
Hypothesis: A nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia (1988) (24)
Transforming Growth Factors β1 and β2 in the Cerebrospinal Fluid of Chronic Schizophrenic Patients (1997) (24)
THYROTROPIN-RELEASING HORMONE IN CHRONIC SCHIZOPHRENIA (1975) (24)
Effect of chronic caffeine administration oh monoamine and monoamine metabolite concentratiows in rat brain (1990) (24)
Baclofen treatment in chronic schizophrenia: a clinical trial. (1977) (24)
Phenylethylamine excretion in depression (1984) (24)
Defect symptoms and abnormal involuntary movement in schizophrenia (1986) (24)
Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients. (1979) (23)
Apomorphine response and subtyping of schizophrenia (1983) (23)
Partial reversal of the iminodipropionitrile-induced hyperkinetic syndrome in rats by alpha-tocopherol (vitamin E). (1988) (23)
New directions in the prevention and treatment of schizophrenia: a biological perspective. (1996) (23)
The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital. (1989) (23)
Improved selective ion monitoring mass-spectrometric assay for the determination of N,N-dimethyltryptamine in human blood utilizing capillary column gas chromatography. (1979) (23)
A method for sleep depriving rats (1977) (23)
The dimethyltryptamine-forming enzyme in blood platelets: a study in monozygotic twins discordant for schizophrenia. (1973) (23)
Chronic lithium treatment prevents the dexamethasone-induced increase of brain polyamine metabolizing enzymes. (1992) (23)
The effects of desipramine, zimelidine, electroconvulsive treatment and lithium on rat brain biogenic amines: a comparison with peripheral changes. (1986) (22)
A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. (1977) (22)
MRI changes during water loading in patients with polydipsia and intermittent hyponatremia. (1999) (22)
Phenylethylamine (PEA) and phenylacetic acid (PAA) in the urine of chronic schizophrenic patients and controls. (1980) (22)
Clinical and Laboratory Studies with Selective Monoamine-Oxidase-Inhibiting Drugs (1983) (22)
Transplantation of eyes to the adult rat brain: histological findings and light-evoked potential response. (1980) (22)
Postmortem central catecholamines and antemortem cognitive impairment in elderly schizophrenics and controls. (1985) (22)
Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice (2004) (21)
Longitudinal studies of the effect of monoamine oxidase inhibitors on sleep in man (1969) (21)
Increased Serum Calcium and Phosphorus with the ‘Switch’ into Manic or Excited Psychotic States (1979) (21)
d-DOPA and l-DOPA similarly elevate brain dopamine and produce turning behavior in rats (1988) (21)
Ventricular enlargement in child psychiatric patients: a controlled study with planimetric measurements. (1983) (21)
Schizophrenia: perchance a dream? (1975) (21)
Sleep disturbance and serum CPK activity in acute psychosis. (1970) (21)
Different effects of amphetamine and amfonelic acid on peripheral and central catecholamine metabolism. (1980) (21)
Prolactin response to beta-endorphin in man. (1980) (21)
Neuroleptics and the Natural Course of Schizophrenia 325 (2005) (20)
Accumulation of exogenous polyamines in gerbil brain after ischemia. (1993) (20)
A clinical trial of nifedipine in schizophrenia and tardive dyskinesia (1991) (20)
Dopamine-beta-hydroxylase, monoamine oxidase, and schizophrenia. (1980) (20)
Blink rates and receptor supersensitivity (1981) (19)
Binding of 3H-spiperone to human peripheral lymphocytes: Absence of stereospecific high-affinity binding (1989) (19)
Fenfluramine and chronic schizophrenia (1985) (19)
Drug withdrawal in chronic schizophrenic patients: in search of neuroleptic-induced supersensitivity psychosis. (1981) (19)
Serum haloperidol concentration and clinical response in schizophrenia. (1988) (19)
Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system (1999) (19)
Serum aluminum in primary degenerative dementia. (1980) (19)
Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings (1991) (19)
Transplantation Techniques and the Survival of Adrenal Medulla Autografts in the Primate Brain (1987) (19)
SCHIZOPHRENIA AND CEREBRAL ATROPHY (1980) (19)
Interaction of potassium and calcium in penicillin-induced interictal spike discharge in the hippocampal slice (1978) (19)
5-Methoxy-N,N-dimethyltryptamine: behavioral and toxicological effects in animals. (1976) (18)
Difficulties in comparing catecholamine-related enzymes from the brains of schizophrenics and controls. (1978) (18)
The Genain quadruplets 25 years later: A diagnostic and biochemical followup (1984) (18)
Lymphocyte monoamine oxidase activity and chronic schizophrenia (1980) (18)
Use of VA aftercare following military discharge among patients with serious mental disorders. (2003) (18)
Marijuana: differential effects on right and left hemisphere functions in man. (1977) (18)
White House Cases: psychiatric patients and the Secret Service. (1985) (18)
The effects of phenylethylamine in rhesus monkeys. (1978) (18)
N,N-dimethyltryptamine--a possible relationship to schizophrenia? (1974) (18)
Effects of chronic cocaine treatment on rat brain: Long-term reduction in frontal cortical serotonin (1994) (18)
A comparison of two iatrogenic dyskinesias. (1983) (18)
Improving accuracy in the diagnosis of Alzheimer's disease. (1983) (18)
Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects (1982) (18)
PLASMA DOPAMINE-BETA-HYDROXYLASE IN IDENTICAL TWINS DISCORDANT FOR SCHIZOPHRENIA (1974) (18)
Vanilmandelic acid (VMA), free and conjugated 3-methoxy-4-hydroxyphenylglycol (MHPG) in human ventricular fluid. (1975) (17)
An effect of neuroleptic medication on plasma dopamine-beta-hydroxylase activity. (1981) (17)
Effect of probenecid on the concentration of the lumbar cerebrospinal fluid acidic metabolites of tyramine, octopamine, dopamine and norepinephrine. (1977) (17)
Low dose bromocriptine: A study of acute effects in chronic medicated schizophrenics (1984) (17)
Serum Enzyme Changes during Sleep Deprivation (1970) (17)
Cutaneous histamine response in schizophrenia. (1980) (17)
Scienceless to homeless. (1986) (17)
P-chlorophenylalanine trials in schizophrenic patients. (1982) (17)
Reduced haloperidol: Effects on striatal dopamine metabolism and conversion to haloperidol in the rat (2004) (17)
The regulation of insulin-induced and sleep-related human growth hormone secretion: A review (1979) (16)
Effects of marihuana on contingent negative variation and reaction time. (1974) (16)
Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose (2005) (16)
The Assessment and Clinical Implications of Haloperidol Acute‐Dose, Steady‐State, and Withdrawal Pharmacokinetics (1993) (16)
Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. (1995) (16)
Regional Differences in Rat Brain Dopamine Transporter Binding: Function of Time After Chronic Cocaine (1993) (16)
Dopamine effect on the mitochondria potential in B lymphocytes of schizophrenic patients and normal controls (2002) (16)
Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia (1992) (16)
Expression of the cholecystokinin gene in rat brain during development. (1987) (16)
CALCIUM AND MALIGNANT CATATONIA (1977) (15)
Lifetime monoamine oxidase inhibition and sleep (1982) (15)
MONOAMINE OXIDASE AND SCHIZOPHRENIA (1982) (15)
Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man (1981) (15)
Plasma and cerebrospinal fluid concentration of phenylacetic acid in humans and monkeys. (1983) (15)
Correlation between plasma concentrations of chlorpromazine and clinical response. (1978) (15)
Lack of evidence for a role of T-cell-associated retroviruses as an etiology of schizophrenia (1989) (15)
Search for cytomegalovirus in the postmortem brains of schizophrenic patients using the polymerase chain reaction. (1992) (15)
Increased cyclic AMP response to forskolin in Epstein-Barr virus-transformed human B-lymphocytes derived from schizophrenics (1997) (15)
Zinc and copper in patients with schizophrenia. (1982) (15)
Dementia in the presenium (1974) (15)
Neuroleptics attentuate stereotyped behavior induced by beta-phenylethylamine in rats. (1978) (14)
Localization of Met5-enkephalin-Arg6-Phe7-like immunoreactivity in the rat gastrointestinal tract (1984) (14)
Possible interference by the reduced haloperidol metabolite with the radioimmunoassay and radioreceptor assay of blood haloperidol. (1984) (14)
On the enzymatic hydrolysis of the sulfate conjugate of 3-methoxy-4-hydroxyphenylglycol (MHPG). (1980) (14)
The dopamine hypothesis: variations on a theme (II). (1986) (14)
6-[18F]Fluoro-L-DOPA and Cerebral Blood Flow in Unilaterally MPTP-Treated Monkeys (1993) (14)
In vivo PET studies of the dopamine D1 receptors in rhesus monkeys with long‐term MPTP‐induced Parkinsonism (2002) (14)
Clinical and laboratory studies with selective monoamine-oxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects. (1983) (14)
The serotonin-catecholamine-dream bicycle: a clinical study. (1972) (14)
Vincent van Gogh's illness. (1992) (14)
Selective reduction in dopamine turnover in the rat frontal cortex and hypothalamus during withdrawal from repeated cocaine exposure. (1994) (14)
A comparative study on the effects of morphine on central, peripheral and ganglionic stores of catecholamines. (1981) (14)
Effects of genotype on age-related alterations in the concentrations of stress hormones in plasma and hypothalamic monoamines in rats. (1993) (14)
Biochemical and Pharmacological Characteristics of Conjugated Catecholamines in the Rat Brain (1983) (14)
Enzyme Studies in Tardive Dyskinesia. III. Noradrenergic Hyperactivity in a Subgroup of Dyskinetic Patients (1982) (14)
Different effects of behaviorally equipotent doses of amphetamine and methamphetamine on brain biogenic amines: specific increase of phenylethylamine by amphetamine. (1982) (14)
The inhibitory effect of intraventricular administration of serotonin on spontaneous motor activity of rats (1976) (13)
Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. (1997) (13)
Cerebral ventricular enlargement and dopamine synthesis inhibition in chronic schizophrenia. (1980) (13)
Creatine kinase and enolase: intracellular enzymes serving as markers of central nervous system damage in neuropsychiatric disorders. (1992) (13)
An endogenous inhibitor of platelet MAO activity in chronic schizophrenia: failure to replicate. (1979) (13)
Prevention and management of tardive dyskinesia. (1985) (13)
Cerebrospinal fluid zinc concentrations in ex-heroin addicts and patients with schizophrenia: some preliminary observations. (1982) (13)
Urinary phenethylamine response to d-amphetamine in 12 boys with attention deficit disorder. (1984) (13)
Increased renal neuroleptic binding in spontaneously hypertensive rats. (1980) (13)
Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-dopa uptake in brain. (1992) (13)
Dose response and time course effects of N,N-dimethyltryptamine on disruption of rat shuttlebox avoidance. (1977) (13)
PROPRANOLOL AND PROLACTIN (1977) (12)
Low plasma levels of CPZ in patients chronically treated with neuroleptics. (1978) (12)
The continued search for evidence of retroviral infection in schizophrenic patients (1991) (12)
Calculating the Cost of Schizophrenia (1987) (12)
PLATELET MONOAMINE OXIDASE AND PLASMA DOPAMINE β-HYDROXYLASE IN TARDIVE DYSKINESIA (1979) (12)
Physostigmine alters onset but not duration of REM sleep in man (1978) (12)
Emergency management of the starving psychiatric patient. (1980) (12)
First psychiatric hospitalizations in the US military: the National Collaborative Study of Early Psychosis and Suicide (NCSEPS) (2006) (12)
Enlarged Cerebral Ventricles in Schizophrenia (1983) (12)
Effects of chronic D-amphetamine and phenylethylamine on the concentrations of neurotransmitter amino acids in the rat brain. (1983) (11)
Chronic cocaine effects on peripheral biogenic amines: a long-term reduction in peripheral dopamine and phenylethylamine production. (1988) (11)
Neurochemical Aspects of Schizophrenia (1985) (11)
Soares & McGrath—The treatment of tardive dyskinesia: a systematic review and meta-analysis (1999) (11)
Serum parathyroid hormone concentrations in senile dementia (Alzheimer's disease). (1980) (11)
Deficient natural killer cell (NK) activity and macrophage functioning in schizophrenic patients (2005) (11)
Potentiation of amphetamine-induced hyperactivity by acute but not by chronic para-chlorophenylalanine treatment in the rat. (1976) (11)
Some kinetic parameters of platelet monoamine oxidase in chronic schizophrenia (1979) (11)
Monoamine oxidase, phenylethylamine, norepinephrine and schizophrenia (1981) (11)
CSF copper concentrations in chronic schizophrenia. (1983) (11)
The interpretation of plasma haloperidol concentrations. (1985) (11)
Similar Incidence Worldwide of Schizophrenia: Case not Proven (1987) (11)
N5,10-methylenetetrahydrofolate reductase activity in autopsied brain parts of chronic schizophrenics and controls and in vitro tryptoline formation. (1978) (10)
PROPRANOLOL TREATMENT OF CHRONIC SCHIZOPHRENIA: CLINICAL RESPONSE, CATECHOLAMINE METABOLISM AND LYMPHOCYTE β-RECEPTORS (1979) (10)
Amphetamine Psychosis—A Model for Paranoid Schizophrenia? (1978) (10)
Effects of morphine on norepinephrine turnover in various functional regions of rat spinal cord. (1982) (10)
The indole hallucinogens, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), have different effects from mescaline on rat shuttlebox avoidance (1978) (10)
Hydra head activator peptide has trophic activity for eukaryotic neurons. (1992) (10)
Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia. (1981) (10)
Effects of smoking during antipsychotic withdrawal in patients with chronic schizophrenia (2000) (10)
Tolerance and dependence to serotonin. A speculation. (1973) (10)
Is vigor of regeneration a key factor in recovery from peripheral nerve injuries? (1986) (10)
Effects of a selective inhibitor of type A monoamine oxidase--Lilly 51641--on behavior, sleep and circadian rhythms in depressed and schizophrenic patients. (1978) (10)
Presence and distribution of phenylethylamine in the rat spinal cord (1981) (10)
γ-Butyrolactone-sensitive and -insensitive dopamine release, and their relationship to dopamine metabolism in three rat brain regions (1992) (10)
Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis (2003) (10)
Effect of altered calcium ion concentration on interictal spike generation in the hippocampal slice (1980) (10)
Effects of chronic haloperidol on caudate 3H-spiroperidol binding in lesioned rats. (1979) (10)
Chronic haloperidol treatment attenuates receptor-mediated phosphoinositide turnover in rat brain slices (1991) (10)
Nitric oxide induces cell death in a catecholaminergic cell line derived from the central nervous system (1998) (10)
Research Design Issues: Antialuminum Drug Studies in Alzheimer's Disease (1982) (10)
Catatonic stupor and neuroleptic drugs. (1978) (10)
Postinjection L-phenylalanine increases basal ganglia contrast in PET scans of 6-18F-DOPA. (1991) (9)
Dopamine release in the rat cerebellum and hippocampus: a tissue 3-methoxytyramine study (1994) (9)
Disparate serum thioridazine concentrations: liquid chromatography versus radioreceptor assay. (2009) (9)
Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. (1993) (9)
Reverse transcriptase activity in 5-azacytidine-treated lymphocyte cultures of patients with schizophrenia (1988) (9)
Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP (1999) (9)
Tetrahydrocannabinol (THC): metabolism and subjective effects. (1976) (9)
Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients (1973) (9)
The relationship between urine excretion and biogenic amines and their metabolites in cerebrospinal fluid of schizophrenic patients (1996) (9)
Evidence for and against the involvement of N,N-dimethyl-tryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in schizophrenia. (1976) (9)
Biochemical characterization of the rat sympathetic ganglion: pharmacological effects of reserpine on ganglionic catecholamines. (1979) (9)
Lithium Revisited: Savings Brought About by the Use of Lithium, 1970–1991 (2004) (9)
Clozapine and Tardive Dyskinesia-Reply (1983) (8)
Biochemistry and schizophrenia III. A review of childhood psychosis. (1975) (8)
Platelet methylene reductase activity in schizophrenia. (1977) (8)
TOPOGRAPHIC ANALYSIS OF COMPUTER PROCESSED ELECTROENCEPHALOGRAPHY IN SCHIZOPHRENIA (1982) (8)
A sensitive and rapid fluorimetric assay for monoamine oxidase utilizing high pressure liquid chromatography. (1980) (8)
The Transmethylation Hypothesis: A Quarter of a Century Later (1976) (8)
Serum Creatine Phosphokinase Elevations in Patients with Tardive Dyskinesia (1993) (8)
5-HYDROXYTRYPTOPHAN AND CHRONIC SCHIZOPHRENIA - A PRELIMINARY STUDY (1973) (8)
Part II. Sleep Studies (1971) (8)
INTERACTIONS OF HALLUCINOGENS AT THE CLINICAL LEVEL (1976) (8)
Increased serotonin turnover in corpus striatum following an injection of kainic acid: Evidence for neuronal feedback regulation of synthesis (1979) (8)
Wheat gluten impedes absorption of haloperidol. (1978) (8)
Basal ganglia iron in tardive dyskinesia: an MRI study (1994) (8)
Deprivation of rapid eye movement sleep and nesting behavior in rats (1977) (8)
Relationships between platelet and plasma monoamine oxidase, plasma dopamine-beta-hydroxylase, and urinary 3-methoxy-4-hydroxy phenylglycol. (1975) (8)
The Effects of Acute and Chronic Haloperidol Treatment on Dopamine Release Mediated by the Medial Forebrain Bundle in the Striatum and Nucleus Accumbens (1996) (7)
Transplantation of dopamine-containing tissues to the central nervous system. (1983) (7)
Neuroleptics and tardive dyskinesia--quo vadis? (1982) (7)
NAD glycohydrolase: enzyme characterization using intact mammalian erythrocytes. (1982) (7)
Alpha-adrenergic receptors and cyclic AMP production in a group of schizophrenic patients. (1986) (7)
Family and biologic variables in the same etiologic studies of schizophrenia: a proposal. (1975) (7)
The determination of urinary 3-methoxy-4-hydroxyphenylglycol excretion in acute schizophreniform and depressed patients. (1983) (7)
Phenylethylamine, Tyramine and Other Trace Amines in Patients with Affective Disorders: Associations with Clinical State and Antidepressant Drug Treatment (1984) (7)
Ventricular fluid 5-hydroxyindoleacetic acid concentrations during human sleep. (1974) (7)
Affective Disorders and Schizophrenia (1977) (7)
Adrenergic and Dopaminergic Response to Chronic Chair Restraint in the Rhesus Monkey (1979) (7)
Tardive Dyskinesia: The Syndrome (1980) (7)
Production of convulsions in mice by the combination of methionine and homocysteine (1980) (7)
Monoamine oxidase activity in brains from schizophrenic and mentally normal individuals (2004) (7)
Sexual physiology and schizophrenia. (1977) (6)
DNA repair and mutant frequency in schizophrenia. (1991) (6)
Increased spontaneous eye-blinks cerebellectomized rats. (1981) (6)
Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not gamma-butyrolactone-resistant dopamine release. (1993) (6)
INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA: A FOLLOW-UP STUDY (1979) (6)
Transplanting tissue into the brain for function: use in a model of Parkinson's disease. (1986) (6)
Amelioration of Psychosis with Carbidopa: A Case Report (1984) (6)
Post lumbar-puncture headaches in schizophrenic and psychiatrically normal control subjects (2005) (6)
Risk factors for spontaneous dyskinesia (1993) (6)
Behavioral effects of amfonelic acid in rats: a comparison with amphetamine and apomorphine. (1979) (6)
Psychopathology and dyskinesia. (1984) (6)
Aluminum-fluoride complexes: preclinical studies. (1985) (6)
Calcitonin: aversive effects in rats? (1981) (6)
Magnetic resonance imaging evaluation of brain iron levels (1995) (6)
A signal analysis approach to rat sleep scoring instrumentation. (1980) (6)
The tryptolines: Effect of intraventricular administration on spontaneous motor activity of rats (1976) (6)
Propranolol in high doses increases plasma prolactin concentrations in male rats. (1980) (6)
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate (1995) (6)
Effects of chronic nicotine and haloperidol administration on muscarinic receptor-mediated phosphoinositide turnover in rat brain slices (2005) (5)
Metabolism of carbidopa to alphamethyldopamine and alphamethylnorepinephrine in rats (1985) (5)
Expression of neurotrophic activity in Xenopus oocytes injected with mRNA from wounded rat cerebral cortex. (1990) (5)
Effect of exertion on the stimulation of ornithine decarboxylase activity by growth hormone in rats. (1989) (5)
Embryonic brain grafts in an animal model of Parkinson's disease. Criteria for human application. (1984) (5)
ANIMAL MODELS OF DRUG-INDUCED HALLUCINATIONS (1978) (5)
Effects of water loading in schizophrenic patients with polydipsia-hyponatremia: an MRI pilot study (1994) (5)
A Method for Shortening of the Rat Spine and its Neurologic Consequences (1993) (5)
774 The effect of nifedipine on tardive dyskinesia: A double blind study in eighteen patients (1997) (5)
Platelet monoamine oxidase activity and human sleep. (1978) (5)
S-adenosylmethionine-dependent N-methyltransferase activity in autopsied brain parts of chronic schizophrenics and controls. (1978) (5)
Questions About the Dopaminergic Nature of [3H]GBR‐12935 Binding in the Human Frontal Cortex (1994) (5)
Reversible tardive dyskinesia: implications for therapeutic strategy and prevention of tardive dyskinesia. (1983) (5)
Peripheral Catecholamine Enzyme Function and Cognitive Impairment of Elderly Schizophrenics and Controls (1984) (5)
Human leukocyte antigen A2 and psychopathology in chronic schizophrenia. (1980) (5)
Relationship between tryptophan and serotonin concentrations in postmortem human brain. (1987) (5)
Behavioral supersensitivity to beta-phenylethylamine after chronic administration of haloperidol. (1984) (5)
Development of differences in response latencies to right and left visual fields (1984) (5)
CATECHOLAMINE RELATED SUBSTANCES AND SCHIZOPHRENIA: A REVIEW (1979) (4)
Effect of chronic cocaine withdrawal on dopamine uptakes sites in the rat frontal cortex (1989) (4)
The time and space machine: Continuous measurement of drug-induced behavior patterns in the rat (2004) (4)
The Origin, Drug Interaction, Urine, Plasma and CSF Concentrations of Phenylacetic Acid in Normal and Psychiatric Subjects (1984) (4)
Disruption of conditioned avoidance behavior by n,n-dimethyltryptamine (DMT) and stereotype by beta-phenylethylamine (PEA): animal models of attentional defects in schizophrenia. (1978) (4)
pros-Methylimidazoleacetic acid in cerebrospinal fluid of patients with chronic schizophrenia: relationships to ratings of symptoms, ventricular brain ratios, and rates of urine excretion. (1996) (4)
Cholinergic Modulation of Sleep, Growth Hormone and Analgesia in Normal Volunteers (1978) (4)
U.S. birth cohort studies of schizophrenia: a sea change. (2000) (4)
A high affinity GTP binding site in rat brain. (1980) (4)
The effect of early neuroleptic intervention on the course of schizophrenia (1991) (4)
Practical psychiatric practice : forms and protocols for clinical use (1998) (4)
The effect of oral glucose on platelet monoamine oxidase. (1982) (4)
Tolerance to the increased locomotor activity produced by l-5-hydroxytryptophan following peripheral decarboxylase inhibition in mice (1978) (4)
Baclofen: lack of effect on human plasma prolactin. (1978) (4)
Enzyme Studies in Tardive Dyskinesia. II. Familial Aspects (1982) (4)
Schizophrenia and intellectual decline. (1998) (4)
Wheat gluten and haloperidol. (1980) (4)
Tardive Dyskinesia and Subtyping of Schizophrenia (1986) (4)
Questions About the Dopamine Terminals in Human Frontal Cortex (1995) (4)
Platelet monoamine oxidase: Studies on the rate of heat inactivation in normal and in paranoid and nonparanoid chronic schizophrenic groups (1979) (4)
Chapter 81 An improved procedure for pressure-free insertion of tissue into the central nervous system (1988) (3)
PHENYLETHYLAMINE (PEA) AND CHRONIC SCHIZOPHRENIA (1979) (3)
Future Directions for Biological Exploration of Psychiatric Disorders (1984) (3)
Spontaneous dyskinesia in schizophrenia (1995) (3)
Monoamine oxidase inhibitors potentiate phenylethylamine effects in rhesus monkeys. (1980) (3)
Platelet monoamine oxidase in an aged general population and elderly chronic schizophrenics [[proceedings]. (1981) (3)
Future Research Directions in the Treatment of Schizophrenia (1984) (3)
Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report. (1996) (3)
Adverse events during a placebo phase for inpatients with chronic schizophrenia (2001) (3)
The effect of probenecid on the free and conjugaed 3-methoxy-4-hydroxyphenylglycol (MHPG) in lumbar cerebrospinal fluid. (1976) (3)
RBC and plasma choline in neuroleptic-treated schizophrenic patients (1989) (3)
A screening method using tissue culture for evaluation of potential retinal adhesives. (1989) (3)
paraChlorophenylalanine potentiates facilitatory effects of Mescaline on shuttlebox escape/avoidance in rats (1976) (3)
DNA repair and mutant frequency in schizophrenia (1992) (3)
Failure to find interference between anti-HLA antibodies and chlorpromazine (1990) (3)
Phenylethylamine in rhesus monkeys: interactions with alpha-methyl-para-tyrosine and l-dopa. (1979) (3)
A novel method for measuring benzodiazepines in saliva. (1979) (3)
Pharmacogenetics of phenylethylamine: Determination of heritability and genetic transmission of locomotor effects in recombinant inbred strains of mice (2004) (3)
Urinary Dopamine Metabolites During Cocaine Abstinence (1995) (3)
Differential distribution of type A and B monoamine oxidase in neuronal tissues. (1977) (3)
Schizophrenic outcome in late life: Symptom state and platelet monoamine oxidase activity (1984) (3)
Effects of dopamine synthesis inhibition on WAIS comprehension. (1978) (2)
Evaluation of cyclic AMP accumulation in EBV-transformed human B-lymphocytes: Effects of dopamine agonists, isoproterenol, prostaglandin E1, cholera toxin, forskolin, and phorbol 12-myristate-13 acetate (1996) (2)
Improving the Orientation of Nerve Regrowth with a Simple Device (1992) (2)
768 The prevalence of spontaneous dyskinesia in never-medicated patients with schizophrenia and other psychiatric disorders (1997) (2)
VAN GOGH : MENIERE'S DISEASE ? EPILEPSY ? PSYCHOSIS ?. AUTHOR REPLY (1991) (2)
The Search for Circulating Sleep-Promoting Factors (1982) (2)
Consensus Statement: The National Depressive and Manic-Depressive Association Consensus Statement on the Undertreatment of Depression (1997) (2)
Development to tolerance of and dependence on endogenous neurotransmitters. (1975) (2)
Plasma concentrations of some acidic and alcoholic metabolites derived from m- and p-tyramine, octopamine and catecholamines in humans. (1977) (2)
An Introduction to Sleep Studies (1977) (2)
Early intervention in schizophrenia improves the long-term course of the illness (1995) (2)
Narcolepsy and Diseases of Excessive Sleep (1977) (2)
paraChlorophenylalanine potentiates facilitatory effects of mescaline on shuttlebox escape/avoidance in rats (2004) (2)
589 The effect of nifedipine on akathisia and agitation in patients with movement disorders (1997) (2)
A Pharmacologic Approach to Sleep Studies (1977) (2)
DMT—A possible relationship to schizophrenia (1974) (2)
Neurotransmitter-related enzymes in the major psychiatric disorders: II. MAO and DBH in schizophrenia. (1975) (2)
Analysis of cerebrospinal fluid monoamines in schizophrenic patients on and off neuroleptic treatment and compared with healthy controls (1991) (2)
Presynaptic dopamine function in schizophrenia: An 18F-DOPA pet study (1995) (2)
Effect of chronic haloperidol treatment on dopamine-induced inositol phosphate formation in rat brain slices (1994) (2)
Metabolism of carbidopa to alpha-methyldopamine and alpha-methylnorepinephrine in rats. (1985) (2)
Effects on humans of A9-trahydrocannahiiioI administered by smoking. (1972) (2)
Van Gogh: Meniere's Disease? Epilepsy? Psychosis? (1991) (2)
Piperidine in chronic schizophrenic patients: a controlled double-blind study. (1981) (2)
Inhibition of neuroleptic binding by human brain extracts--an effect of endogenous dopamine? (1985) (2)
Dopamine-responsive neurotrophic factor in schizophrenia (1995) (2)
Neurobehavioral evaluation of function following experimental nerve damage. (1984) (2)
Guidelines for the Use of Neuroleptics in Clinical Practice (1980) (2)
Tardive Dyskinesia: A Review of the Treatment Possibilities (1980) (2)
Capillary column gas-liquid chromatography selected ion monitoring assay for [13C, 15N]N-methyltryptamine in human urine: failure to detect conversion of [13C,15N]tryptamine in schizophrenia patients. (1984) (2)
VITAMIN E TREATMENT OF TARDIVE DYSKINESIA. REPLY (1993) (1)
gamma-Butyrolactone-sensitive and -insensitive dopamine release, and their relationship to dopamine metabolism in three rat brain regions. (1992) (1)
Dopamine transporter changes in schizophrenia (1995) (1)
Polydipsia-hyponatremia: Evidence for specific cerebral structural pathology and implications for the pathophysiology of schizophrenia (1991) (1)
Saliva benzodiazepine levels and clinical outcome in detoxifying alcoholic patients. (1980) (1)
Local autoimmune reaction and behavioral abnormalities after repeated nerve injury: an experimental study. (1988) (1)
Schizophrenia and publication: epilogue. (1978) (1)
An improved procedure for pressure-free insertion of tissue into the central nervous system. (1988) (1)
Testosterone-attenuated stereotype and hyperactivity induced by beta-phenylethylamine in pargyline-pretreated rats. (1978) (1)
Lymphocytic monoamine oxidase: activity and thermolability in younger and older subjects. (1984) (1)
Are chlorpromazine dose equivalents equivalent in serum? (1981) (1)
Letter: Thyrotropin-releasing hormone in chronic schizophrenia. (1975) (1)
Tolerance development to a disruptive effect of β-phenylethylamine (PEA) on a learned behavior in rats (1979) (1)
Striatal Presynaptic Dopaminergic Function and Cerebral Blood Flow in the MPTP Primate Model of Parkinson’s Disease by PET (1990) (1)
Clonidine Does Not Potentiate the Antipsychotic Effects of Neuroleptics in Chronically Ill Patients (1998) (1)
Morphine attenuates rod and cone components of the human electroretinogram (1987) (1)
Guest Editorial: Neuroleptics and Tardive Dyskinesia—Quo Vadis? (1982) (1)
Alcohol, Alcoholism, and the Problem of Dependence (1977) (1)
Pet study of the dopamine neurotransmitter dependent tracer 6-18F-DOPA in schizophrenia (1993) (1)
Interferon and Immunoglobulin G as Immunological Markers in Chronic Schizophrenia (1991) (1)
BIOCHEMICAL APPROACHES TO PHYSIOLOGIC SUBTYPING OF SCHIZOPHRENIA (1992) (1)
Schizophrenia research in the Intramural Research Program, National Institute of Mental Health: editor's introduction. (1988) (1)
Evidence against depolarization block hypothesis of the mechanism of action of antipsychotic drugs: Effects of tetrodotoxin infusion into the median forebrain bundle after acute and chronic neuroleptic treatment (1993) (1)
Neurotransmitter-related enzymes in the major psychiatric disorders: I. Catechol-O-methyl transferase, monoamine oxidase in the affective disorders, and factors affecting some behaviorally correlated enzyme activities. (1975) (1)
Intravenous chlorimipramine affects REM cycle in patients with excessive daytime sleepiness and control subjects. (1980) (1)
Studies of Norepinephrine in Schizophrenia (1985) (1)
Response: homelessness. (1987) (1)
New Experimental Approaches Examining a Viral Etiology of Schizophrenia (1991) (1)
Decreased dopamine transporter receptors in the anterior cingulate cortex of schizophrenic patients (1995) (1)
SCHIZOPHRENIA AND CEREBRAL ATROPHY (1980) (1)
Effects of antipsychotics, vitamin E, and MK-801 on dopamine dynamics in the rat brain following discontinuation of cocaine (1998) (1)
Editorial and Overview (1984) (0)
2518 – DIFFERENT EFFECTS OF AMPHETAMINE AND AMFENOLIC ACID ON PERIPHERAL AND CENTRAL CATECHOLAMINE METABOLISM (1978) (0)
The interpersonal impact approach to patient assessment: Specific links between psychotics' symptoms and staff's feelings (1984) (0)
Characterization of dopamine uptake sites in the human and rat frontal cortex (1989) (0)
Characterization of 3H-GBR 12935 binding to the dopamine transporter in human frontal cortex and its relevance to schizophrenia (1989) (0)
first intemational symposium on drugs as discriminative stimuli (2004) (0)
Letter from Richard J. Wyatt to Joshua Lederberg (1978) (0)
Editorial: Biological Psychology/Pharmacopsychology (1985) (0)
Sequence of alcohol presentation is important in the potentiation of long-term events (1983) (0)
Dispositif d'analyse des anomalies de déplacement de rats de laboratoire (1997) (0)
Dr. Egan and Colleagues Reply (1993) (0)
THE NEUROPHARMACOLOG Y OF SLEEP AND WAKEFULNESS (1978) (0)
The multiple monoamine oxidases. (1974) (0)
2523 – REGULATION OF CATECHOLAMINE TURNOVER AND METABOLISM IN THE RAT SYMPATHETIC GANGLIA (1978) (0)
A CROSS-CULTURAL DESIGN TO TEST A BIOLOGICAL HYPOTHESIS OF SCHIZOPHRENIA (1982) (0)
Editorial: Biological Psychiatry/Pharmacopsychiatry (1985) (0)
50 – BIOBEHAVIORAL CORRELATES OF SLEEP IN ETHANOL DEPENDENT RATS (1978) (0)
PHYSOSTIGMINE ANTAGONISM OF MORPHINE-INDUCED RESPIRATORY DEPRESSION (1981) (0)
Economic savings and clozapine. (1995) (0)
A parameter of the dark-adapted electroretinogram correlates with ratings of positive symptoms and abnormal involuntary movements in chronic schizophrenic subjects (1989) (0)
Calcitonin as an Anorectic Agent (1984) (0)
An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia (1995) (0)
Messages from afar. (1988) (0)
L-Histidine: Failure to affect the sleep-waking cycle in man (2004) (0)
Pharmacological responsiveness of [3H]GBR 12935 binding sites in the prefrontal cortex of cocaine using humans and rats (1994) (0)
More on diagnosing Alzheimer's disease. (1984) (0)
Elevated Phenylethylamine Excretion in Women (1985) (0)
The authors reply (1986) (0)
Current concepts of schizophrenia. Introduction. (1976) (0)
PHARMACOLOGICAL CHARACTERIZATION OF CATECHOLAMINE NEURONS IN THE RAT SYMPATHETIC GANGLION (1979) (0)
18 F-DOPA PET study of the presynaptic dopamine function in schizophrenia (1995) (0)
S-67-4 Antipsychotics limit deterioration in schizophrenic illness (1996) (0)
22. Dopamine transporter in schizophrenia: A progressive loss with age in the cingulate cortex (1996) (0)
All-Cause and Suicide Mortality in Discharged us Military Personnel with Severe Psychiatric Disorders (2006) (0)
Dr. Luchins and Associates Reply (1979) (0)
690 – 5-HYDROXYTRYPTOLINE: PHARMACOLOGICAL ACTIONS (1977) (0)
2308 – TNCREASED SEROTONIN TURNOVER IN STRIATUM FOLLOWING KAINIC ACID (1978) (0)
Computed Tomography in Tardive Dyskinesia (1980) (0)
The anterior cingulate cortex in schizophrenia: Decreased dopamine and possible mechanism for its occurrence (1996) (0)
79-3 Treatment with antipsychotic medications may prevent the long-term deterioration in schizophrenia (1997) (0)
Vincent van Gogh: A Psychological Study (1967) (1990) (0)
S-56-2 Schizophrenia: A neurodevelopmental and progressive disorder (1996) (0)
The relationship between urine excretion and biogenic amines and their metabolites in cerebrospinal fluid of schizophrenic patients (Schizophrenia Research 19 (1996) 171–176) (1996) (0)
Wyatt ’ s Practical Psychiatric Practice : Forms and Protocols for Clinical Use ( 3 rd edn ) (2006) (0)
S-69-2 Spontaneous dyskinesia and psychopathology in the pre-neuroleptic era (1996) (0)
Book Review A Beautiful Mind By Sylvia Nasar. 459 pp., illustrated. New York, Simon & Schuster, 1998. $25. 0-684-81906-6 (1998) (0)
Clinical Studies of Insomnia (1977) (0)
Vincent van Gogh's illness [21] (1992) (0)
ISERDTDNIN FUNCTION AND GENDER EFFECTS IN MIGRAINE PRODUCTION AND DCD (2012) (0)
384. Early intervention in schizophrenia improves the long-term course of the illness (1996) (0)
SCHIZOPHRENIA AND INTELLECTUAL DECLINE. AUTHORS' REPLY (1998) (0)
Are the regional differences in [3H]GBR 12935 binding clinically relevant? (1994) (0)
PRODUCTIVE PERSON YEARS: A NEW METHOD FOR UNDERSTANDING MEDICAL COSTS (1994) (0)
Tissue 3-methoxytyramine in the rat cerebellum and hippocampus A potential index of dopamine release (1994) (0)
Annotation: Hypertension inPopulations ofAfrican Origin (1997) (0)
2013 Daniel H. Efron Research Award (2012) (0)
Is Bromocriptine a Dopamine Antagonist Treatment?-Reply (1983) (0)
1434 – 5-MTHF MEDIATED FORMATION OF TRYPTOLINES (TETRAHYDRO-β-CARBOLINES) BY HUMAN BRAIN (1977) (0)
vacuous chewing movements in rodents: incidence and effects of long.term increases in haloperidoi dose (1995) (0)
Is there any information on the risk of inducing tardive dyskinesia when treating a patient with borderline personality disorder with low dose neuroleptic therapy (1984) (0)
On Sandoz's Claim of Thioridazine's Comparative Safety (1983) (0)
The Adelaide Children's Hospital School. (1975) (0)
Note added to ‘Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: Their relationships to levels of other aminergic transmitters and ratings of symptoms’ Schizophrenia Research 14 (2) 1995 pp 93–104 (1995) (0)
Publisher’s Editorial (1985) (0)
CD5+ B lymphocytes and the effects of continuous haloperidol decanoate and coenzyme-q10: An animal model of immunologic anomalies in schizophrenia (1993) (0)
Clinical Phenomenology CHAIRPERSON (2005) (0)
Cerebrospinal fluid proteins in schizophrenia: functional markers for blood-brain barrier permeability and central nervous system immunoglobulin production (1989) (0)
Dr. Wyatt and Dr. Khot Reply (2006) (0)
A biochemical comparison of long-term cocaine administration and schizophrenia (1993) (0)
Weight change during various neuropharmacologic manipulations in psychotic inpatients. (1978) (0)
CSF neurotrophic activity in schizophrenia (1993) (0)
821 Effects of repeated footshock stress on dopamine metabolism and tyrosine hydroxylase activity in the brains of fisher rats (1997) (0)
After Middle Age; A Physician's Guide to Growing Old and Staying Healthy (1985) (0)
Determination of heritability and genetic transmission of locomotor effects in recombinant inbred strains of mice (1984) (0)
A functional assessment of disability scale for tardive dyskinesia (1994) (0)
Altered cyclic amp response to forskolin and cholera toxin after protein kinas C activation in EBV-transformed B-lymphocytes from schizophrenics (1995) (0)
Paramethoxyphenylethylamine (PMPEA): some behavioral observations in rats. (1977) (0)
Age dependent changes in dopamine transporter binding and its relevance to schizophrenia (1991) (0)
Phenelzine and psychosis. (1976) (0)
HLA AND REVERSED CEREBRAL ASYMMETRIES: POSSIBLE MARKERS FOR A SUBGROUP OF SCHIZOPHRENICS (1982) (0)
Increased adenylate cyclase activity and rapid weight loss following intraseptal injection of cholera toxin. (1978) (0)
Response (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard Jed Wyatt?

Richard Jed Wyatt is affiliated with the following schools:

Richard Jed Wyatt's Academic­Influence.com Rankings

Why Is Richard Jed Wyatt Influential?

Richard Jed Wyatt's Published Works

Published Works

What Schools Are Affiliated With Richard Jed Wyatt?

Richard Jed Wyatt's AcademicInfluence.com Rankings